MedWatch

EU approves first SGLT-2-class diabetes drug

The first product in the so-called SGLT-2-klass of drugs against type 2 diabetes has won backing from the European Union.

Foto: LIND OLE

The major players on the lucrative market for diabetes medicine face new competition from the first ever approved product in the newest class of drugs against type 2 diabetes – the so-called SGLT-2 drugs, as Astrazeneca and Bristol-Myers Squibb have had the pill Forxiga, which works independently of traditional insulin, approved for the European markets.

“We are excited about the approval of FORXIGA in Europe, and the significant advancement it represents for the many millions of European patients with type 2 diabetes who need new options to manage this progressive disease,” says Pascal Soriot, Chief Executive Officer, AstraZeneca, in a press release.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier